Table 1 Patients characteristics (n = 356)
From: Androgen receptor status is highly conserved during tumor progression of breast cancer
Features | n (%) |
|---|---|
Age at diagnosis | median 67 yrs (range:31–98) |
Histological subtypes | |
No special type (NST) | 253 (71.1) |
Lobular | 51 (14.3) |
Mucinous | 13 (3.7) |
Carcinoma with medullary-like features | 11 (3.1) |
Ductulo-lobular | 6 (1.7) |
Tubular | 4 (1.1) |
Micropapillary | 3 (0.8) |
Cribriform | 2 (0.6) |
Glycogen rich | 1 (0.3) |
Mixed | 12 (3.3) |
Grading (Nottingham) | |
G1 | 41 (11.5) |
G2 | 194 (54.5) |
G3 | 121 (34.0) |
T-category (UICC 7th edition) | |
T1 | 150 (42.1) |
T2 | 167 (46.9) |
T3 | 21 (5.9) |
T4 | 18 (5.1) |
N-category (UICC 7th edition) | |
N0 | 146 (41.0) |
N1mi | 18 (5.1) |
N1 | 102 (28.6) |
N2 | 27 (7.6) |
N3 | 22 (6.2) |
no lymph nodes | 41 (11.5) |
Estrogen receptor | |
positive (≥1 %) | 308 (86.5) |
negative (<1 %) | 48 (13.5) |
Progesterone receptor | |
positive (≥1 %) | 258 (72.5) |
negative (<1 %) | 98 (27.5) |
Her2 Status | |
positive | 37 (10.4) |
negative | 316 (88.7) |
Equivocal | 1 (0.3) |
no data | 2 (0.6) |
Proliferation fraction (MIB-1) | |
High (≥20 %) | 57 (16.0) |
low (<20 %) | 297 (83.4) |
no data | 2 (0.6) |
Molecular subtypes (St. Gallen 2013) | |
Luminal A | 197 (55.4) |
Luminal B (Her2 negative) | 82 (23.1) |
Luminal B (Her2 positive) | 24 (6.7) |
Her2 | 10 (2.8) |
Triple negative | 35 (9.8) |
no data | 8 (2.2) |